Vol. 6, Issue 1, Part A (2024)

Background: D-dimer is a fibrin degradation product that is commonly used as a biomarker to assess the presence of thrombotic activity in various clinical settings. While D-dimer is primarily associated with the diagnosis of venous thromboembolism, aortic dissection and peripheral artery diseases. This trial aimed to evaluate whether the level of D-dimer can predict in-hospital adverse outcome following primary PCI for STEMI.
Patients and Methods: This was a prospective work was performed at Cardiology department on Two hundred participants who assigned into two groups. Group 1: involved 150 participants with normal level D-dimer <0.5 mg/l and Group 2: involved 50 participants with increased D-dimer level >0.5 mg/ l 
Results: A substantially more participants presented with reduced LVEF in group (2) in comparison with group (1). D-dimer and peak troponin were substantially greater in group (2) in comparison with group (1). There were substantially more patients presented with No-reflow in group (2) in comparison with group (1) 36% vs 18% respectively. There was long hospital stay in group (2) contrasted to group (1). D-dimer level was substantially higher among individuals with MACE as contrasted to individuals without MACE 1.46 vs 0.5 respectively.
Conclusion: An elevated D-dimer levels had been shown to be an independent factor of risk for MACE during hospitalization among individuals with STEMI who received primary PCI, this includes cases with no-reflow and angiographically evident thrombus (AET). The cutoff value was 0.6 mg/l.